Moleculin Biotech (MBRX) Competitors $0.51 +0.02 (+4.76%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$0.51 0.00 (-0.41%) As of 10/8/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MBRX vs. ORMP, HLVX, MEIP, ADVM, ATRA, ANEB, OVID, APLT, IPA, and COYAShould you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Oramed Pharmaceuticals (ORMP), HilleVax (HLVX), MEI Pharma (MEIP), Adverum Biotechnologies (ADVM), Atara Biotherapeutics (ATRA), Anebulo Pharmaceuticals (ANEB), Ovid Therapeutics (OVID), Applied Therapeutics (APLT), ImmunoPrecise Antibodies (IPA), and Coya Therapeutics (COYA). These companies are all part of the "pharmaceutical products" industry. Moleculin Biotech vs. Its Competitors Oramed Pharmaceuticals HilleVax MEI Pharma Adverum Biotechnologies Atara Biotherapeutics Anebulo Pharmaceuticals Ovid Therapeutics Applied Therapeutics ImmunoPrecise Antibodies Coya Therapeutics Oramed Pharmaceuticals (NASDAQ:ORMP) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations. Which has more risk and volatility, ORMP or MBRX? Oramed Pharmaceuticals has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500. Do insiders & institutionals believe in ORMP or MBRX? 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 17.8% of Oramed Pharmaceuticals shares are held by insiders. Comparatively, 3.4% of Moleculin Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has better valuation & earnings, ORMP or MBRX? Oramed Pharmaceuticals has higher revenue and earnings than Moleculin Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOramed Pharmaceuticals$1.34M73.13-$19.06M-$0.35-6.83Moleculin BiotechN/AN/A-$21.76MN/AN/A Does the media refer more to ORMP or MBRX? In the previous week, Oramed Pharmaceuticals had 1 more articles in the media than Moleculin Biotech. MarketBeat recorded 2 mentions for Oramed Pharmaceuticals and 1 mentions for Moleculin Biotech. Oramed Pharmaceuticals' average media sentiment score of 0.95 beat Moleculin Biotech's score of 0.91 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oramed Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moleculin Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ORMP or MBRX? Moleculin Biotech has a consensus target price of $4.00, indicating a potential upside of 687.25%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Moleculin Biotech is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is ORMP or MBRX more profitable? Oramed Pharmaceuticals' return on equity of -19.37% beat Moleculin Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Oramed PharmaceuticalsN/A -19.37% -18.28% Moleculin Biotech N/A -1,498.41%-114.47% SummaryOramed Pharmaceuticals beats Moleculin Biotech on 8 of the 12 factors compared between the two stocks. Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBRX vs. The Competition Export to ExcelMetricMoleculin BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.01M$3.35B$6.10B$10.55BDividend YieldN/A2.28%5.69%4.75%P/E RatioN/A21.5785.4727.60Price / SalesN/A427.64582.22224.03Price / CashN/A47.1237.9261.55Price / Book0.2910.1413.136.76Net Income-$21.76M-$52.31M$3.30B$275.88M7 Day Performance1.62%5.14%4.29%2.81%1 Month Performance24.84%14.68%9.45%9.24%1 Year Performance-80.07%30.98%86.64%35.42% Moleculin Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBRXMoleculin Biotech2.9965 of 5 stars$0.51+4.8%$4.00+687.2%-79.7%$24.01MN/A0.0020Analyst ForecastORMPOramed Pharmaceuticals1.472 of 5 stars$2.58-2.3%N/A+2.6%$105.79M$2M-7.3710Analyst ForecastHLVXHilleVax1.085 of 5 stars$2.09flat$2.00-4.3%N/A$104.79MN/A-1.4620MEIPMEI Pharma1.0138 of 5 stars$3.19+14.7%N/A+17.7%$104.72MN/A-0.67100Gap UpHigh Trading VolumeADVMAdverum Biotechnologies3.9176 of 5 stars$4.78+5.4%$19.75+313.6%-35.9%$100.70M$1M-0.61190Analyst ForecastATRAAtara Biotherapeutics4.6236 of 5 stars$14.34+0.1%$21.00+46.4%+102.2%$100.70M$128.94M-33.36330News CoverageAnalyst ForecastANEBAnebulo Pharmaceuticals2.812 of 5 stars$2.44-2.2%$5.50+125.0%+21.7%$100.40MN/A-9.404Analyst ForecastGap DownOVIDOvid Therapeutics4.5813 of 5 stars$1.37+5.4%$3.10+126.3%+43.6%$97.42M$6.65M-2.5860Analyst ForecastAPLTApplied Therapeutics3.5427 of 5 stars$0.68+12.4%$4.13+506.6%-86.9%$97.06M$121K-1.5030Gap DownHigh Trading VolumeIPAImmunoPrecise Antibodies1.0806 of 5 stars$2.10+8.5%$4.00+90.9%+233.3%$96.68M$17.59M-3.0880Positive NewsGap UpCOYACoya Therapeutics2.3652 of 5 stars$5.75+0.8%$16.20+182.0%-9.8%$96.11M$3.55M-4.636Analyst Forecast Related Companies and Tools Related Companies ORMP Competitors HLVX Competitors MEIP Competitors ADVM Competitors ATRA Competitors ANEB Competitors OVID Competitors APLT Competitors IPA Competitors COYA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MBRX) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
